← SynDRA
VILDAGLIPTIN
SynDRA canonical compound SYN0004825 — structure-anchored drug synonym record
| Clinical phase | Launched |
|---|
| Primary target(s) | DPP4 |
|---|
| Mechanism of action | Dipeptidyl peptidase inhibitor |
|---|
| Indication | diabetes mellitus |
|---|
| Disease area | endocrinology |
|---|
All known targets
- DPP4
- DPP IV
- DPP8
- DPP9
- FAP
- Fap
Mechanisms of action (all sources)
- Dipeptidyl peptidase inhibitor
- DPP4 inhibitor
Drug classes
- Dipeptidyl-Peptidase IV Inhibitors
- Enzyme Inhibitors
- Hypoglycemic Agents
- Protease Inhibitors
ATC classes
- A10B · BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
Cross-references
Synonyms
- xiliarx
- galvus
- jalra
- NVP-LAF237
- vildagliptin hydrochloride
- vildagliptin HCl
- Vildagliptine
- Vildagliptina
- Vitagliptin
- LAF-237
- LAF237
- NVP-LAF 237
- Equa
- Galvus
- Jalra
- Xiliarx
- Galvu
- Galvus (TN)
- Vidagliptin (see Vildagliptin)
- Vildagliptin (JAN/USAN/INN)
- (2S)-(((3-hydroxyadamantan-1-yl)amino)acetyl)pyrrolidine-2-carbonitrile
- (2S)-1-[2-[(3-hydroxy-1-adamantyl)amino]acetyl]pyrrolidine-2-carbonitrile
- 1-[2-[(3-hydroxy-1-adamantyl)amino]acetyl]pyrrolidine-2-carbonitrile
- 2-Pyrrolidinecarbonitrile, 1-[[(3-hydroxytricyclo[3.3.1.13,7]dec-1-yl)amino]acetyl]-, (2S)-(9CI)
- NVP LAF237
- LAF 237
- NVP-LAF-237
- vildagliptine
- I6B4B2U96P
- vildagliptinum
- RefChem:6349
- DTXCID501508682
- Vildagliptin (LAF-237)
- Vildagliptin [USAN]
- UNII-I6B4B2U96P
- Zomelis
- Zomelis;
- Galvus;
Look up VILDAGLIPTIN in the interactive SynDRA portal →